Trial results

A Research Study to Investigate the Effects of CagriSema Compared to Placebo in People With Type 2 Diabetes and Painful Diabetic Peripheral Neuropathy

NCT06797869 on ClinicalTrials.gov · last registry update 2025-12-05

Closed to new participants; the 142 already enrolled are still being followed. Its estimated completion date, 21 August 2026, has passed with no update to the record. Primary outcome, as filed: Change in weekly average Pain Intensity-Numerical Rating Scale (PI-NRS). A lapsed estimate is not a result and not a failure — sponsors are slow to refile — but ClinicalTrials.gov marks it nowhere on the record, so it is noted here. semaglutide is already approved in the US for type 2 diabetes, so this is asking a further question rather than establishing the drug works at all.

Status

ACTIVE_NOT_RECRUITING

Phase

P2

Drug

semaglutide

Wegovy, Ozempic, Rybelsus

Sponsor

Novo Nordisk A/S

Sponsor type

Industry

Enrollment

142

Started

2025-01-29

Primary completion

2026-08-21 estimated

Observed history

No changes recorded since monitoring began on 2026-08-21. This record has held steady. If a reporting date moves, a status changes or enrollment is resized, it will appear here with the previous value alongside the new one.

Primary outcome

Change in weekly average Pain Intensity-Numerical Rating Scale (PI-NRS)

Conditions studied

Diabetes Mellitus, Type 2 · Diabetic Peripheral Neuropathy

Every field above is taken directly from the registry record. See all detected changes across the class, or the semaglutide page for this molecule’s full trial and approval history.